Adherium – BioScience Managers

Adherium Announces Participation in SmartAirLA Effort to Combat Asthma in Los Angeles with Support from Blue Shield of California Foundation

3rd October 2018/in Adherium

03 Oct 2018 Adherium (ASX:ADR), a leading digital health platform for medication adherence today announced its participation in the launch of the SmartAirLA program to empower communities to reduce the effects and prevalence of asthma in Los Angeles through Internet of Things technology. Using Adherium’s Hailie™ solution, SmartAirLA will help patients with asthma and COPD […]

Adherium and Vitalus Health Launch Commercial Program to Support Patients with Asthma and COPD

23rd August 2018/in Adherium

23 Aug 2018 San Mateo, CA – August 23, 2018: Adherium (ASX:ADR) a digital health platform focused on improving medication adherence and patient outcomes, and Vitalus Health, a leading provider of comprehensive health and wellness solutions that focus on pulmonary disease management, today announced a broadened strategic program encompassing Adherium’s Hailie™ solution. With the expansion of its […]

Adherium and Asthma and Respiratory Foundation NZ Collaborate to Improve Outcomes for Asthma Patients, with a Special Focus on New Zealand Children

20th August 2018/in Adherium

21 August 2018 – Asthma and Respiratory Foundation NZ announces today that it has agreed to work with Adherium to improve outcomes for asthma patients, with a special focus on New Zealand children and teenagers, in a collaboration to be known as the Kiwi Kids Program. Adherium is an an award-winning digital health company that improves medication […]

Adherium Launches Hailie™ Solution Direct-to-Consumer in the U.S. for Better Asthma and COPD Management

13th August 2018/in Adherium, Uncategorised

13 Aug 2018 San Mateo, CA – August 13th, 2018: Adherium (ASX: ADR), a leading digital health platform that focuses on improving medication adherence and patient outcomes, today officially launched the Hailie™ solution in the U.S., following its recent Food and Drug Administration (FDA) 510(k) over-the-counter clearance to enable sales direct to consumers. The Hailie solution […]

Adherium Receives Additional U.S. FDA 510(k) Clearance, Setting in Motion a Full U.S. Consumer Launch of the Hailie™ Solution

26th July 2018/in Adherium

26 Jul 2018 San Mateo, CA – July 26, 2018: Adherium (ASX: ADR), an award-winning digital health platform that improves medication adherence, patient outcomes and engagement, today announced the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for over-the-counter (OTC) sales of its Hailie™ sensor for use with ProAir® HFA, Ventolin® HFA and Flovent® […]

Adherium Announces Patient Program with Connecticut Children’s Medical Center to Explore Best Practices for Access to Better Asthma Care Nationally

10th July 2018/in Adherium

10 Jul 2018 San Mateo, CA – July 10, 2018: Adherium (ASX: ADR), a leading digital health company that improves medication adherence and patient outcomes, today announced a patient program with Connecticut Children’s Medical Center to help patients with asthma manage their condition with Adherium’s technology, the Hailie™ solution. Connecticut Children’s Medical Center’s close work with the […]

Adherium’s Technology Used for Large Scale Electronic Data Capture in Landmark Mild-Asthma Trials

18th May 2018/in Adherium, BioSciences Managers

18 May 2018 San Mateo, CA – May 18, 2018: Adherium (ASX: ADR), a digital health company that improves medication adherence and patient outcomes, announced the extensive use of it’s Hailie™(previously known as Smartinhaler™) technology in two landmark clinical trials investigating the treatment of mild asthma, which have just been published in the New England Journal […]

Adherium Launches the Hailie™ Global Brand to Connect People with Asthma and COPD to Better Care

17th May 2018/in Adherium, BioSciences Managers

17 May 2018 San Mateo, CA – May 16th, 2018: Adherium (ASX: ADR), an award-winning digital health company that improves medication adherence, patient outcomes and engagement, today announced the launch of the Hailie™ global brand to connect people with asthma and COPD to better care. The launch is a rebrand of the existing Smartinhaler™ brand, and […]

Adherium Announces Program with Vitalus Health on World Asthma Day

1st May 2018/in Adherium, BioSciences Managers

01 May 2018 San Mateo, CA – May 1, 2018: In conjunction with World Asthma Day, Adherium (ASX: ADR), a digital health company that improves medication adherence and patient outcomes, announced today it has agreed to launch a program with Vitalus Health, targeting patients with chronic obstructive pulmonary disease (COPD) using the Adherium Smartinhaler technology. Vitalus […]

Adherium Receives U.S. 510(k) Clearance for Over-the-Counter Sales of its Smartinhaler™ Sensor

27th March 2018/in Adherium, BioSciences Managers

San Mateo, CA – March 27, 2018: Adherium (ASX: ADR), a digital health company that improves medication adherence and patient outcomes, today announced the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for over-the-counter (OTC) sales of its SmartinhalerTM sensor for AstraZeneca’s Symbicort® aerosol asthma inhaler. The Smartinhaler sensor is a device installed onto a […]